Article
Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial.
JAMA neurology - 1 Aug 2022
Pan Yuesong, Meng Xia, Jin Aoming, Johnston S Claiborne, Li Hao, Bath Philip M, Xie Xuewei, Jing Jing, Lin Jinxi, Wang Yilong, Zhao Xingquan, Li Zixiao, Jiang Yong, Liu Liping, Yang Hongqin, Cheng Jiwei, Wang Zhimin, Wang Yongjun
Abstract excerpt
Importance: Dual antiplatelet therapy (DAPT) with ticagrelor and aspirin has been found to be effective for secondary prevention after minor ischemic stroke or transient ischemic attack (TIA) in individuals who carry CYP2C19 loss-of-function (LOF) alleles; however, uncertainties remain about the time course of benefit and risk with ticagrelor and aspirin in these patients. Objective: To obtain time-course...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.